Toll-like receptors in urothelial cells - Targets for cancer immunotherapy

Nature Reviews Urology

Volumn 10, Issue 9, 2013, Pages 537-545

  Larue, Hélène ^a   Ayari, Cherifa ^a   Bergeron, Alain ^a   Fradet, Yves ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CXCL1 CHEMOKINE; I KAPPA B; INTERFERON REGULATORY FACTOR 3; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CYTOTOXICITY; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTERNALIZATION; MYCOBACTERIUM BOVIS; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TIGHT JUNCTION; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; TOLL-LIKE RECEPTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84883739946     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.153     Document Type: Review

References (116)

1. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur. Urol. 59, 997-1008 (2011).
2. Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
3. van Rhijn, B. W. et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur. Urol. 56, 430-442 (2009).
4. Brausi, M. et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J. Urol. 186, 2158-2167 (2011).
5. Feifer, A. H., Taylor, J. M., Tarin, T. V. & Herr, H. W. Maximizing cure for muscle-invasive bladder cancer: Integration of surgery and chemotherapy. Eur. Urol. 59, 978-984 (2011).
6. van den Bosch, S. & Alfred, W. J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: A systematic review. Eur. Urol. 60, 493-500 (2011).
7. Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. & Hauser, R. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 21, 1315-1330 (2003).
8. Herr, H. W. et al. Intravesical bacillus Calmette-Guerin therapy prevents tumour progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 13, 1404-1408 (1995).
9. Malmstrom, P. U. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur. Urol. 56, 247-256 (2009).
10. Kresowik, T. P. & Griffith, T. S. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 1, 281-288 (2009).
11. Brandau, S. & Suttmann, H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement. Biomed. Pharmacother. 61, 299-305 (2007).
12. Birder, L. A. Urinary bladder urothelium: Molecular sensors of chemical/thermal/mechanical stimuli. Vascul. Pharmacol. 45, 221-226 (2006).
13. Bevers, R. F., Kurth, K. H. & Schamhart, D. H. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br. J. Cancer 91, 607-612 (2004).
14. Lattime, E. C., Gomella, L. G. & McCue, P. A. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T- cells. Cancer Res. 52, 4286-4290 (1992).
15. Tsuji, S. et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: Involvement of toll-like receptors. Infect. Immun. 68, 6883-6890 (2000).
16. Miyazaki, J. et al. Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guerin through Toll-like receptor signalling. BJU Int. 97, 860-864 (2006).
17. Mendez-Samperio, P., Belmont, L. & Miranda, E. Mycobacterium bovis BCG Toll-like receptors 2 and 4 cooperation increases the innate epithelial immune response. Arch. Med. Res. 39, 33-39 (2008).
18. Simons, M. P., O'Donnell, M. A. & Griffith, T. S. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol. 26, 341-345 (2008).
19. Ayari, C., Bergeron, A., LaRue, H., Menard, C. & Fradet, Y. Toll-like receptors in normal and malignant human bladders. J. Urol. 185, 1915-1921 (2011).
20. Akira, S., Uematsu, S. & Takeuchi, O. Pathogen recognition and innate immunity. Cell 124, 783-801 (2006).
21. Zhang, Z. & Schluesener, H. J. Mammalian toll-like receptors: From endogenous ligands to tissue regeneration. Cell Mol. Life Sci. 63, 2901-2907 (2006).
22. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11, 373-384 (2010).
23. Li, X., Jiang, S. & Tapping, R. I. Toll-like receptor signalling in cell proliferation and survival. Cytokine 49, 1-9 (2010).
24. Kawai, T. & Akira, S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650 (2011).
25. Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003).
26. Yamamoto, M. & Takeda, K. Current views of toll-like receptor signalling pathways. Gastroenterol. Res. Pract. 240, 365 (2010).
27. Zahringer, U., Lindner, B., Inamura, S., Heine, H. & Alexander, C. TLR2 -promiscuous or specific? A critical re-evaluation of a receptor apparent broad specificity. Immunobiology 213, 205-224 (2008).
28. Hashimoto, M. et al. Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J. Immunol. 177, 3162-3169 (2006).
29. Tsan, M. F. & Gao, B. Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors. J. Endotoxin Res. 13, 6-14 (2007).
30. Travassos, L. H. et al. Toll-like receptor 2-dependent bacterial sensing does not occur via peptidoglycan recognition. EMBO Rep. 5, 1000-1006 (2004).
31. Schilling, J. D. et al. CD14-and toll-like receptor-dependent activation of bladder epithelial cell by lipopolysaccharide and type 1 piliated Escherichia coli. Infect. Immun. 71, 1470-1480 (2003).
32. Khandelwal, P., Abraham, S. N. & Apodaca, G. Cell biology and physiology of the uroepithelium. Am. J. Physiol. Renal Physiol. 297, F1477-F1501 (2009).
33. Song, J. & Abraham, S. N. TLR-mediated immune responses in the urinary tract. Curr. Opin. Microbiol. 11, 66-73 (2008).
34. Hooton, T. M. & Stamm, W. E. Diagnosis and treatment of uncomplicated urinary tract infection. Infect. Dis. Clin. North Am. 11, 551-581 (1997).
35. Song, J., Bishop, B. L., Li, G., Duncan, M. J. & Abraham, S. N. TLR4-initiated and cAMP-mediated abrogation of bacterial invasion of the bladder. Cell Host Microbe 1, 287-298 (2007).
36. Hagberg, L. et al. Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect. Immun. 46, 839-844 (1984).
37. Shahin, R. D., Engberg, I., Hagberg, L. & Svanborg, E. C. Neutrophil recruitment and bacterial clearance correlated with LPS responsiveness in local gram-negative infection. J. Immunol. 138, 3475-3480 (1987).
38. Suhs, K. A., Marthaler, B. R., Welch, R. A. & Hopkins, W. J. Lack of association between the Tlr4 (Lpsd/Lpsd) genotype and increased susceptibility to Escherichia coli bladder infections in female C3H/HeJ mice. MBio. 2, e00094-e00111 (2011).
39. Agnese, D. M. et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J. Infect. Dis. 186, 1522-1525 (2002).
40. Karoly, E. et al. Heat shock protein 72 (HSPA1B) gene polymorphism and Toll-like receptor (TLR) 4 mutation are associated with increased risk of urinary tract infection in children. Paediatr. Res. 61, 371-374 (2007).
41. Ragnarsdottir, B. et al. Reduced toll-like receptor 4 expression in children with asymptomatic bacteriuria. J. Infect. Dis. 196, 475-484 (2007).
42. Godaly, G. & Svanborg, C. Urinary tract infections revisited. Kidney Int. 71, 721-723 (2007).
43. Fischer, H., Yamamoto, M., Akira, S., Beutler, B. & Svanborg, C. Mechanism of pathogen-specific TLR4 activation in the mucosa: Fimbriae, recognition receptors and adaptor protein selection. Eur. J. Immunol. 36, 267-277 (2006).
44. Svanborg, C. et al. Uropathogenic Escherichia coli as a model of host-parasite interaction. Curr. Opin. Microbiol. 9, 33-39 (2006).
45. Nagai, Y. et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3, 667-672 (2002).
46. Shimizu, T. et al. Membrane-anchored CD14 is important for induction of interleukin-8 by lipopolysaccharide and peptidoglycan in uroepithelial cells. Clin. Diagn. Lab. Immunol. 11, 969-976 (2004).
47. Song, J. & Abraham, S. N. Innate and adaptive immune responses in the urinary tract. Eur. J. Clin. Invest. 38 (Suppl. 2), 21-28 (2008).
48. Song, J. et al. A novel TLR4-mediated signalling pathway leading to IL-6 responses in human bladder epithelial cells. PLoS Pathog. 3, e60 (2007).
49. Ozinsky, A. et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc. Natl Acad. Sci. USA 97, 13766-13771 (2000).
50. Basith, S., Manavalan, B., Yoo, T. H., Kim, S. G. & Choi, S. Roles of toll-like receptors in cancer: A double-edged sword for defence and offense. Arch. Pharm. Res. 35, 1297-1316 (2012).
51. Hawn, T. R. et al. Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women. PLoS ONE 4, e8300 (2009).
52. Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099-1103 (2001).
53. Smith, K. D. et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat. Immunol. 4, 1247-1253 (2003).
54. Andersen-Nissen, E. et al. Cutting edge: Tlr5-/-mice are more susceptible to Escherichia coli urinary tract infection. J. Immunol. 178, 4717-4720 (2007).
55. Hawn, T. R. et al. Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women. PLoS ONE 4, e5990 (2009).
56. Smith, N. J. et al. Toll-like receptor responses of normal human urothelial cells to bacterial flagellin and lipopolysaccharide. J. Urol. 186, 1084-1092 (2011).
57. Zhang, D. et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 303, 1522-1526 (2004).
58. Pinto, A., Morello, S. & Sorrentino, R. Lung cancer and Toll-like receptors. Cancer Immunol. Immunother. 60, 1211-1220 (2011).
59. Niedzielska, I. et al. Toll-like receptors and the tendency of normal mucous membrane to transform to polyp or colorectal cancer. J. Physiol. Pharmacol. 60 (Suppl. 1), 65-71 (2009).
60. Zhou, M. et al. Toll-like receptor expression in normal ovary and ovarian tumours. Cancer Immunol. Immunother. 58, 1375-1385 (2009).
61. Morikawa, T. et al. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin. Cancer Res. 13, 5703-5709 (2007).
62. Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D. & Romero, P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin. Cancer Res. 13, 4565-4574 (2007).
63. Chen, R., Alvero, A. B., Silasi, D. A., Steffensen, K. D. & Mor, G. Cancers take their Toll-The function and regulation of Toll-like receptors in cancer cells. Oncogene 27, 225-233 (2008).
64. Kutikhin, A. G. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signalling pathway with cancer risk. Hum. Immunol. 72, 1095-1116 (2011).
65. Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H. & Xiong, H. TLR signalling by tumour and immune cells: A double-edged sword. Oncogene 27, 218-224 (2008).
66. Shen, Y., Liu, Y., Liu, S. & Zhang, A. Toll-like receptor 4 gene polymorphisms and susceptibility to bladder cancer. Pathol. Oncol. Res. 19, 275-280 (2012).
67. Singh, V., Srivastava, N., Kapoor, R. & Mittal, R. D. Single-nucleotide polymorphisms in genes encoding Toll-like receptor -2, -3, -4, and -9 in a case-control study with bladder cancer susceptibility in a North Indian population. Arch. Med. Res. 44, 54-61 (2013).
68. LaRue, H., Parent-Vaugeois, C., Bergeron, A., Champetier, S. & Fradet, Y. Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer. Int. J. Cancer 71, 986-992 (1997).
69. Qian, Y. et al. TLR4 signalling induces B7-H1 expression through MAPK pathways in bladder cancer cells. Cancer Invest. 26, 816-821 (2008).
70. Yamada, H., Odonnell, M. A., Matsumoto, T. & Luo, Y. Interferon-gamma upregulates toll-like receptor 4 and cooperates with lipopolysaccharide to produce macrophage-derived chemokine and interferon-gamma inducible protein-10 in human bladder cancer cell line RT4. J. Urol. 174, 1119-1123 (2005).
71. Qian, Y. et al. Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signalling. J. Cancer Res. Clin. Oncol. 135, 379-386 (2009).
72. Goutagny, N., Estornes, Y., Hasan, U., Lebecque, S. & Caux, C. Targeting pattern recognition receptors in cancer immunotherapy. Target. Oncol. 7, 29-54 (2012).
73. Hennessy, E. J., Parker, A. E. & O'Neill, L. A. Targeting Toll-like receptors: Emerging therapeutics? Nat. Rev. Drug Discov. 9, 293-307 (2010).
74. So, E. Y. & Ouchi, T. The application of Toll like receptors for cancer therapy. Int. J. Biol. Sci. 6, 675-681 (2010).
75. Kavoussi, L. R., Brown, E. J., Ritchey, J. K. & Ratliff, T. L. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumour response. J. Clin. Invest 85, 62-67 (1990).
76. Hudson, M. A., Brown, E. J., Ritchey, J. K. & Ratliff, T. L. Modulation of fibronectin-mediated Bacillus Calmette-Guerin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res. 51, 3726-3732 (1991).
77. De Reijke, T. M. et al. Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG). Urol. Res. 21, 349-352 (1993).
78. Esuvaranathan, K. et al. Interleukin-6 production by bladder tumours is upregulated by BCG immunotherapy. J. Urol. 154, 572-575 (1995).
79. Bohle, A. & Brandau, S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J. Urol. 170, 964-969 (2003).
80. Suttmann, H. et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res. 66, 8250-8257 (2006).
81. Suttmann, H., Lehan, N., Bohle, A. & Brandau, S. Stimulation of neutrophil granulocytes with Mycobacterium bovis bacillus Calmette-Guerin induces changes in phenotype and gene expression and inhibits spontaneous apoptosis. Infect. Immun. 71, 4647-4656 (2003).
82. Bohle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. & Flad, H. D. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol. 144, 53-58 (1990).
83. Scanga, C. A. et al. MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect. Immun. 72, 2400-2404 (2004).
84. Simmons, D. P. et al. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J. Immunol. 185, 2405-2415 (2010).
85. Huynh, K. K., Joshi, S. A. & Brown, E. J. A delicate dance: Host response to mycobacteria. Curr. Opin. Immunol. 23, 464-472 (2011).
86. Heldwein, K. A. et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J. Leukoc. Biol. 74, 277-286 (2003).
87. Fremond, C. M., Nicolle, D. M., Torres, D. S. & Quesniaux, V. F. Control of Mycobacterium bovis BCG infection with increased inflammation in TLR4-deficient mice. Microbes Infect. 5, 1070-1081 (2003).
88. Godaly, G. & Young, D. B. Mycobacterium bovis bacille Calmette Guerin infection of human neutrophils induces CXCL8 secretion by MyD88-dependent TLR2 and TLR4 activation. Cell Microbiol. 7, 591-601 (2005).
89. von Meyenn, F. et al. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology 211, 557-565 (2006).
90. Uehori, J. et al. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect. Immun. 71, 4238-4249 (2003).
91. Kato, T. et al. Bacillus Calmette-Guerin and BCG cell wall skeleton suppressed viability of bladder cancer cells in vitro. Anticancer Res. 30, 4089-4096 (2010).
92. Murata, M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumours. Cancer Sci. 99, 1435-1440 (2008).
93. Uenishi, Y., Kawabe, K., Nomura, T., Nakai, M. & Sunagawa, M. Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105). J. Microbiol. Methods 77, 139-144 (2009).
94. Akazawa, T. et al. Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion. Cancer Sci. 101, 1596-1603 (2010).
95. Filion, M. C., Lepicier, P., Morales, A. & Phillips, N. C. Mycobacterium phlei cell wall complex directly induces apoptosis in human bladder cancer cells. Br. J. Cancer 79, 229-235 (1999).
96. Filion, M. C. & Phillips, N. C. Therapeutic potential of mycobacterial cell wall-DNA complexes. Expert Opin. Investig. Drugs 10, 2157-2165 (2001).
97. Morales, A. Evolution of intravesical immunotherapy for bladder cancer: Mycobacterial cell wall preparation as a promising agent. Expert Opin. Investig. Drugs 17, 1067-1073 (2008).
98. Morales, A., Phadke, K. & Steinhoff, G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J. Urol. 181, 1040-1045 (2009).
99. Takeshita, F. et al. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167, 3555-3558 (2001).
100. Haemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
101. Atkins, H., Davies, B. R., Kirby, J. A. & Kelly, J. D. Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: A potential therapeutic regime for bladder cancer immunotherapy. Br. J. Cancer 89, 2312-2319 (2003).
102. Ninalga, C., Loskog, A., Klevenfeldt, M., Essand, M. & Totterman, T. H. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumours and evokes protective immunity in murine bladder cancer. J. Immunother. 28, 20-27 (2005).
103. Mangsbo, S. M., Ninalga, C., Essand, M., Loskog, A. & Totterman, T. H. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J. Immunother. 31, 34-42 (2008).
104. Hegele, A. et al. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model. Anticancer Res. 24, 2225-2230 (2004).
105. Hegele, A. et al. Immunostimulatory CpG oligonucleotides reduce tumour burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol. 26, 274-280 (2005).
106. Olbert, P. J. et al. In vitro and in vivo effects of CpG- Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall. Anticancer Res. 29, 2067-2076 (2009).
107. Mangsbo, S. M. et al. Enhanced tumour eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J. Immunother. 33, 225-235 (2010).
108. Codolo, G. et al. HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunol. Immunother. 61, 31-40 (2012).
109. Smith, E. B. et al. Antitumour effects of imidazoquinolines in urothelial cell carcinoma of the bladder. J. Urol. 177, 2347-2351 (2007).
110. Hayashi, T. et al. Intravesical Toll-like receptor 7 agonist R-837: Optimization of its formulation in an orthotopic mouse model of bladder cancer. Int. J. Urol. 17, 483-490 (2010).
111. Falke, J. et al. A preclinical placebo controlled efficacy study with R-837 and TMX-202 in an orthotopic rat bladder cancer model. Eur. Urol. 10, 80 (2011).
112. Falke, J. et al. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with non-muscle invasive bladder cancer. J. Urol. 19, 275-280 (2012).
113. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01731652?term=bladder+cancer+tmx- 101&rank=1 (2013).
114. de Bono, J. S. et al. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin. Cancer Res. 6, 397-405 (2000).
115. Cho, Y. J., Ahn, B. Y., Lee, N. G., Lee, D. H. & Kim, D. S. A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. Vaccine 24, 5862-5871 (2006).
116. Vacchelli, E. et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1, 894-907 (2012).